| Identification | Back Directory | [Name]
Platinate(2-), [(1R,2R)-1,2-cyclohexanediamine-κN1,κN2][diphosphato(4-)-κO,κO'']-, hydrogen (1:2), (SP-4-2)- | [CAS]
1339960-28-9 | [Synonyms]
Imifoplatin
Platinate(2-), [(1R,2R)-1,2-cyclohexanediamine-κN1,κN2][diphosphato(4-)-κO,κO'']-, hydrogen (1:2), (SP-4-2)- | [Molecular Formula]
C6H13N2O7P2Pt- | [MOL File]
1339960-28-9.mol | [Molecular Weight]
482.21 |
| Hazard Information | Back Directory | [Uses]
Imifoplatin (PT-112) is a platinum-based active molecule and a member of the phosphaplatins family. Imifoplatin can induce Apoptosis and exhibits antitumor activity[1][2][3]. | [in vivo]
Imifoplatin (90 mg/kg, i.v., once weekly for 5 weeks) demonstrates potent antitumor immune effects in the CT26 xenograft model[2].
Imifoplatin (90 mg/kg, i.v., once weekly for 7 weeks) shows synergistic antitumor effects in the MC38 xenograft model, especially with PD-1 blockade (Avelumab (HY-108730))[2]. | Animal Model: | MC38 colorectal carcinoma xenograft model in C57BL/6J mice[2] | | Dosage: | 90 mg/kg | | Administration: | Intravenous injection (i.v.), once weekly for 7 weeks | | Result: | Inhibited tumor growth, extended survival; further enhanced survival when combined with PD-1 blockade (Avelumab (HY-108730)). |
| Animal Model: | CT26 colorectal carcinoma xenograft model in BALB/c mice[2] | | Dosage: | 90 mg/kg | | Administration: | Intravenous injection (i.v.), once weekly for 5 weeks | | Result: | Significantly inhibited tumor growth, increased T-cell infiltration, reduced immunosuppressive TAMs. |
| [storage]
Store at -20°C | [References]
[1] Moghaddas S, et, al. Phosphaplatins, next generation platinum antitumor agents: A paradigm shift in designing and defining molecular targets. Inorganica Chimica Acta. 2012 Dec; 393(1): 173-181.
[2] Yamazaki T, et al. PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. Oncoimmunology. 2020 Feb 11;9(1):1721810. DOI:10.1080/2162402X.2020.1721810
[3] Soler-Agesta R, et al. PT-112 induces mitochondrial stress and immunogenic cell death, targeting tumor cells with mitochondrial deficiencies[J]. Cancers, 2022, 14(16): 3851. DOI:10.3390/cancers14163851 |
|
|